LONDON -- With interest rates being at historic lows, stocks such as�GlaxoSmithKline� (LSE: GSK ) (NYSE: GSK ) have offered a remedy for income-seeking investors.
Indeed, the shares currently yield an impressive 4.4% despite rising by more than 30% in the last three years alone. Clearly, it is understandable why the shares usually form a key part of many investors' portfolios.
However, pigeonholing Glaxo as being little more than a source of income is, in my view, a tad unfair.
Of course, we all know the familiar story that the developed world has an ageing population, which will require treatments and health care in future on a larger scale than it currently does. This situation undoubtedly presents an opportunity for health care companies such as Glaxo.
However, the potential for share-price gains also exists over a much shorter investment horizon.
Unlike stable mate�AstraZeneca, Glaxo has successfully managed its portfolio of patented blockbuster products. Indeed, it seems to have avoided a so-called patent cliff -- where old patents expire, there are no new products to replace them, and revenue then declines significantly.
5 Best Stocks To Invest In Right Now: Electronics for Imaging Inc.(EFII)
Electronics For Imaging, Inc. provides color digital print controllers, digital inkjet printers, and business process automation solutions. The company?s Fiery products consist of stand-alone print controllers and servers connected to digital copiers and other peripheral devices; embedded and design-licensed solutions used in digital copiers and multi-functional devices; optional software integrated into controller solutions that include Fiery Central and MicroPress; Entrac, a self-service and payment solution; PrintMe, a mobile printing application; and stand-alone software-based solutions, such as proofing and scanning solutions, including ColorProof XF, Fiery XF, ColorProof eXpress, and Xflow. It also offers industrial inkjet products, including VUTEk super-wide format digital industrial inkjet printers and inks used by billboard graphics printers, commercial photo labs, sign shops, graphic screen printers, specialty commercial printers, and digital graphics providers; Rastek hybrid and flatbed entry level production UV wide format inkjet printers; and Jetrion label and packaging digital inkjet printers, integration solutions, and specialty digital UV inks for primary and secondary label applications, and industrial label or flexible packaging markets. In addition, the company provides advanced professional print software products consisting of print production workflow and management information software, including Monarch, PSI, Logic, PrintSmith, and PrintFlow; Pace, a cloud-based business process automation software; and cloud-based order entry and order management systems, which comprise Digital StoreFront, PrinterSite, and PrintSmith Site. Electronics For Imaging, Inc. offers its products through sales force and distribution arrangements primarily in the Americas, Europe, the Middle East, Africa, and Japan. The company was founded in 1988 and is headquartered in Foster City, California.
Advisors' Opinion:- [By Brian Pacampara]
What: Shares of digital printing technologist Electronics for Imaging (NASDAQ: EFII ) popped 12% today after its quarterly results topped�Wall Street expectations.
- [By shash63]
Electronic For Imaging�� (EFII) second biggest segment, Fiery Controllers, contributed 35% of total revenue. This segment provides controllers for digital printers. The company�� big clients in this segment are Xerox, Ricoh, Konica Minolta, and Canon, contributing 80% of this segment�� revenue. These clients are expected to launch new products in future, thus creating further potential for revenue growth.
- [By Seth Jayson]
Electronics for Imaging (Nasdaq: EFII ) reported earnings on April 18. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Electronics for Imaging beat expectations on revenues and beat expectations on earnings per share.
Top 5 Heal Care Companies To Buy For 2014: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
Top 5 Heal Care Companies To Buy For 2014: Home Federal Bancorp Inc.(HOME)
Home Federal Bancorp, Inc. operates as the holding company for Home Federal Bank that provides financial products and services to consumers and businesses. The company?s deposit products include checking accounts, money market deposit accounts, savings accounts, and certificates of deposits. Its loan products portfolio comprises one-to-four family residential real estate, real estate construction, and commercial and multifamily real estate loans; commercial business loans for various business purposes, such as working capital and equipment financing, and capital and general investment; and consumer loans, including home equity loans and lines of credit, savings account loans, automobile loans, recreational vehicle loans, and personal unsecured loans. The company offers its products and services in the Treasure Valley region of southwestern Idaho, including Ada, Canyon, Elmore, and Gem counties; the Tri-County region of Central Oregon comprising the counties of Crook, Desc hutes, and Jefferson, as well as the communities of Eugene, Grants Pass, and Medford; and Lane, Josephine, Jackson, and Multnomah counties in Western Oregon. As of January 27, 2012, it operated 28 full-service banking offices. The company was founded in 1920 and is headquartered in Nampa, Idaho.
Advisors' Opinion:- [By Sofia Horta e Costa]
Sanofi fell 2.6 percent after withdrawing a U.S. application for a diabetes drug. Cie. Financiere Richemont (CFR) SA dropped 2.3 percent as revenue missed analysts��estimates. Vivendi SA advanced 2.7 percent after saying it will begin a formal study to separate its French phone unit from its media businesses. Home Retail Group Plc (HOME) surged 5.4 percent to a two-year high as sales exceeded projections.
Top 5 Heal Care Companies To Buy For 2014: Santa Fe Gold Corp (SFEG)
Santa Fe Gold Corporation (Santa Fe), incorporated in August 1991, is a mining company. As of June 30, 2012, the Company had four projects: its Summit silver-gold and Ortiz gold projects located in New Mexico, and its Black Canyon mica and Planet micaceous iron oxide projects located in Arizona. The Company has constructed a mill and are developing an underground mine at its Summit silver-gold project. Santa Fe�� Summit operations in southwestern New Mexico are conducted through its wholly owned subsidiary, The Lordsburg Mining Company. Its mica operations in Arizona are conducted through its wholly owned subsidiary, Azco Mica Inc. Santa Fe�� activity in Mexico is conducted through its wholly owned subsidiary, Minera Sandia, S.A. de C.V.
Summit Silver-Gold Project
The Summit silver-gold project includes the underground Summit silver-gold mine and related property consisting of 117 acres of patented mining claims and 740 acres of unpatented mining claims in Grant County, southwestern New Mexico, and the Banner mill, including mineral processing equipment consisting of a crushing and screening plant, a ball mill and a 400 ton-per-day flotation plant, and related property consisting of approximately 1,500 acres of wholly owned and leased patented and unpatented mining claims, located approximately 57 miles south of the Summit mine near Lordsburg, Hidalgo County, New Mexico. It owns and operates the Summit project under the Lordsburg Mining Company, a wholly-owned subsidiary. The Summit silver-gold property is located in Grant County, southwestern New Mexico, near the Arizona state line. The Banner mill site lies 57 miles to the south of the Summit property near the town of Lordsburg, Hidalgo County, New Mexico.
Santa Fe�� holdings at the Summit silver-gold property in Grant County, New Mexico consist of 10 patented federal mining claims totaling approximately 117 acres and 62 unpatented federal mining claims totaling approximately 740 acres. Its holdings at an! d adjacent to the Banner mill site in Hidalgo County, New Mexico consists of 86 wholly owned patented federal mining claims, 16 wholly owned unpatented mining claims, 17 leased patented mining claims and 6 leased unpatented mining claims, aggregating approximately 1,500 acres. All wholly owned claims are held in the name of Lordsburg Mining.
Ortiz Gold Project
The Ortiz Mine Grant, over which the Company holds a lease on the mineral estate underlying 42,297 acres (66 square miles) of segregated surface estate, is located 30 miles by road northeast of Albuquerque, Santa Fe County, New Mexico.
The Ortiz Mine Grant is underlain by mid-Tertiary monzonite and latite porphyry stocks, plugs, dikes and sills that have intruded Paleozoic to early-Tertiary sedimentary rocks. The intrusive rocks are part of the Ortiz Porphyry Belt, which comprises from north to south, the Cerrillos Hills, the Ortiz Mountains, the San Pedro Mountains, and South Mountain.
Black Canyon Mica Project
The Black Canyon mine is located 30 miles north of Phoenix, Arizona, and 3.5 miles west-southwest of Black Canyon City. The Glendale processing plant was located in an industrial area on the west side of Phoenix, Arizona, 47 miles to the south of the mine site. Its property holdings at and around the Black Canyon mine consists of 67 federal unpatented mining claims in Yavapai County, Arizona and nine federal unpatented mill site claims in Maricopa County, Arizona, which in total cover approximately 1,385 acres.
Planet Micaceous Iron Oxide (MIO) Project
The Planet property consists of thirty-one patented mining claims totaling 523 acres located in western Arizona. The Planet property is located in the northwest corner of La Paz County, west central Arizona. The property consists of thirty-one patented mining claims totaling 523 acres, consisting of an area of 3,600 feet wide by 8,000 feet long.
Lordsburg Exploration Project
T! he Compan! y in the the Lordsburg (Virginia) Mining District controls approximately 1,500 acres of prospective ground, the majority of which is comprised of patented mining claims that it owns, and the remainder patented and unpatented mining claims that it leases. As of June 30, 2012, the Company had completed an aerial mapping survey covering 30 square miles, carried out data compilation, conducted detailed geologic mapping and sampling, and conducted a geophysical survey.
Advisors' Opinion:- [By CRWE]
Last Friday, SFEG had shed (-2.31%) down -0.003 at $.127 with 166,050 shares in play at the close (ref. google finance July 19, 2013 ��Close), but don�� let this get you down.
Santa Fe Gold Corporation previously reported it has amended the Mogollon option agreement with Columbus Exploration Corporation (CLX-TSX-V) (formerly Columbus Silver Corporation) under which Santa Fe may earn 100% interest in the Mogollon Project, Catron County, New Mexico. The Mogollon Project encompasses most of the Mogollon district in southwest New Mexico, which has substantial recorded historical production of silver and gold. The project fits Santa Fe�� strategic objective of developing new ore sources to augment ore currently processed though its Lordsburg flotation mill.
- [By CRWE]
Today, SFEG has shed (-11.76%) down -0.016 at $.123 with 30,280 shares in play thus far (ref. google finance Delayed: 10:48AM EDT July 16, 2013), but don�� let this get you down.
Santa Fe Gold Corporation previously reported it has amended the Mogollon option agreement with Columbus Exploration Corporation (CLX-TSX-V) (formerly Columbus Silver Corporation) under which Santa Fe may earn 100% interest in the Mogollon Project, Catron County, New Mexico. The Mogollon Project encompasses most of the Mogollon district in southwest New Mexico, which has substantial recorded historical production of silver and gold. The project fits Santa Fe�� strategic objective of developing new ore sources to augment ore currently processed though its Lordsburg flotation mill.
No comments:
Post a Comment